二价mRNA COVID-19疫苗在预防≥65岁及终末期肾病患者COVID-19相关血栓栓塞事件中的有效性——美国,2022年9月至2023年3月
两项回顾性队列研究纳入美国医疗保险按服务收费的参保者,评估在仅接种原始单价COVID-19疫苗基础上加种二价mRNA疫苗对COVID-19相关血栓栓塞事件的保护效果。≥65岁人群有效性为47%(95%CI=45%-49%),≥18岁接受透析的终末期肾病患者为51%(95%CI=39%-60%)。免疫功能低下者中有效性相近:≥65岁为46%(95%CI=42%-49%),≥18岁终末期肾病患者为45%(95%CI=24%-60%)。
要点
- ≥65岁医疗保险参保者加种二价疫苗后,预防COVID-19相关血栓栓塞事件的有效性为47%(95%CI=45%-49%)。
- ≥18岁接受透析的终末期肾病患者中,二价疫苗有效性为51%(95%CI=39%-60%)。
- 免疫功能低下者中有效性相近:≥65岁为46%(95%CI=42%-49%),≥18岁终末期肾病患者为45%(95%CI=24%-60%)。
核心结论
- 在仅接种原始单价COVID-19疫苗基础上加种二价mRNA疫苗,对预防COVID-19相关血栓栓塞事件具有额外保护效果。
- 为帮助预防COVID-19并发症(包括血栓栓塞事件),成人应及时接种COVID-19疫苗。
研究设计与样本
- 两项回顾性队列研究,纳入美国医疗保险按服务收费的参保者,研究期间为2022年9月4日至2023年3月4日。
- 比较接种二价mRNA COVID-19疫苗后与仅接种原始单价COVID-19疫苗后COVID-19相关血栓栓塞事件的有效性(VE)。
主要发现
- ≥65岁医疗保险参保者中,二价疫苗预防COVID-19相关血栓栓塞事件的有效性为47%(95%CI=45%-49%)。
- ≥18岁接受透析的终末期肾病患者中,二价疫苗有效性为51%(95%CI=39%-60%)。
- 免疫功能低下的≥65岁医疗保险受益人中,有效性为46%(95%CI=42%-49%)。
- 免疫功能低下的≥18岁终末期肾病患者中,有效性为45%(95%CI=24%-60%)。
关键数值与推荐
- ≥65岁医疗保险参保者:有效性47%(95%CI=45%-49%)。
- ≥18岁接受透析的终末期肾病患者:有效性51%(95%CI=39%-60%)。
- 免疫功能低下的≥65岁医疗保险受益人:有效性46%(95%CI=42%-49%)。
- 免疫功能低下的≥18岁终末期肾病患者:有效性45%(95%CI=24%-60%)。
临床怎么用
- 为帮助预防COVID-19并发症(包括血栓栓塞事件),成人应及时接种COVID-19疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 has been associated with an increased risk for thromboembolic events, including ischemic stroke, venous thromboembolism, and myocardial infarction. Studies have reported lower rates of COVID-19-related thromboembolic events among persons who received the COVID-19 vaccine compared with persons who did not, but rigorous estimates of vaccine effectiveness (VE) in preventing COVID-19-related thromboembolic events are lacking. This analysis estimated the incremental benefit of receipt of a bivalent mRNA COVID-19 vaccine after receiving an original monovalent COVID-19 vaccine. To estimate VE of a bivalent mRNA COVID-19 dose in preventing thromboembolic events compared with original monovalent COVID-19 vaccine doses only, two retrospective cohort studies were conducted among Medicare fee-for-service enrollees during September 4, 2022-March 4, 2023. Effectiveness of a bivalent COVID-19 vaccine dose against COVID-19-related thromboembolic events compared with that of original vaccine alone was 47% (95% CI = 45%-49%) among Medicare enrollees aged ≥65 years and 51% (95% CI = 39%-60%) among adults aged ≥18 years with end stage renal disease receiving dialysis. VE was similar among Medicare beneficiaries with immunocompromise: 46% (95% CI = 42%-49%) among adults aged ≥65 years and 45% (95% CI = 24%-60%) among those aged ≥18 years with end stage renal disease. To help prevent complications of COVID-19, including thromboembolic events, adults should stay up to date with COVID-19 vaccination.
引用
- Payne AB, Novosad S, Wiegand RE, et al. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease - United States, September 2022-March 2023. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38206877. doi:10.15585/mmwr.mm7301a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。